SLC13A5 and metabolic dysfunction-associated steatotic liver disease: Several recent reports have described successful efforts to target the transporting activity of INDY and novel compounds have been identified that demonstrate the therapeutic potential of mINDY inhibitors in the treatment of NAFLD and insulin resistance.